Related Experiment Videos
Bioavailability of intranasal scopolamine in normal subjects
L Putcha1, K J Tietze, D W Bourne
1Biomedical Operations and Research Branch, NASA-Johnson Space Center, Houston, TX 77058, USA.
Journal of Pharmaceutical Sciences
|August 1, 1996
Summary
Intranasal scopolamine offers superior bioavailability compared to oral forms, providing a rapid and effective delivery method. This noninvasive route demonstrates significant potential for scopolamine administration.
Area of Science:
- Pharmacology
- Drug Delivery Systems
Background:
- Scopolamine is a medication used for various conditions, including motion sickness and postoperative nausea.
- Optimizing scopolamine delivery is crucial for effective therapeutic outcomes.
Purpose of the Study:
- To compare the bioavailability of scopolamine across intravenous (i.v.), intranasal (i.n.), and oral (p.o.) dosage forms.
- To evaluate the pharmacokinetic and pharmacodynamic profiles of different scopolamine administration routes.
Main Methods:
- Twelve healthy male volunteers received 0.4-mg scopolamine doses via i.v., i.n., or p.o. routes.
- Plasma scopolamine concentrations were measured using liquid chromatography-radioreceptor binding assay.
- Salivary flow rate suppression was assessed to determine drug effect.
Main Results:
- Intranasal and oral scopolamine showed rapid absorption, with peak plasma concentrations achieved within 1 hour.
- Intranasal scopolamine bioavailability was significantly higher (83%) than oral (3.7%).
- Both i.n. and i.v. routes effectively suppressed salivary flow rate.
Conclusions:
- The intranasal route provides a noninvasive, reliable, and fast method for scopolamine administration.
- Intranasal scopolamine exhibits significantly enhanced bioavailability compared to the oral route.
- Further research into intranasal scopolamine delivery is warranted.